Projects per year
Personal profile
Research interests
Research Expertise:
Organic & Medicinal Chemistry | Organoboron Chemistry | Alternate Energy Materials
Medicinal Chemistry: We have been developing novel aza- and bora-heterocyclic compounds and betulin-based natural product derivatives as anti-cancer agents. In collaboration with Rowan School of Osteopathic Medicine, we have also identified few Withaferin-serotonin conjugates as potential therapeutic options for the treatment of Alzheimers’ Disease.
Value Added Chemicals from Biomass: Recent efforts in this area have included the development of new protocols for the effective conversion of biomass derived cellulosic materials into chemicals such as hydroxymethyl furfural and furan dicarboxylic acid for applications as bio-based polymers.
Honors and Awards:
Rowan University Wall of Fame Teaching Award, 2013, 2016
Eli Lilly International Graduate Scholar, 2000-2005, Purdue University
Member of:
American Chemical Society (www.acs.org)
Education/Academic qualification
Doctor of Philosophy, doctorate
Bachelor of Science, Bachelor, Pondicherry University
Master of Science, Master, University of Hyderabad
Fingerprint
Dive into the research topics where Subash Jonnalagadda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
-
-
Research and Development of Topical and Intravenous Formulations
6/1/16 → 5/31/17
Project: Other project
-
-
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
Al-Odat, O. S., Guirguis, D. A., Schmalbach, N. K., Yao, G., Budak-Alpdogan, T., Jonnalagadda, S. C. & Pandey, M. K., Jan 2023, In: International Journal of Molecular Sciences. 24, 1, 644.Research output: Contribution to journal › Review article › peer-review
Open Access2 Scopus citations -
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Elbezanti, W. O., Challagundla, K. B., Jonnalagadda, S. C., Budak-Alpdogan, T. & Pandey, M. K., Mar 2023, In: Pharmaceuticals. 16, 3, 415.Research output: Contribution to journal › Review article › peer-review
Open Access1 Scopus citations -
Cancer on fire: role of inflammation in prevention and treatment
Pandey, M. K., Von Suskil, M., Chitren, R., Al-Odat, O., Jonnalagadda, S. C. & Aggarwal, B. B., Jan 1 2022, Current Advances for Development of Functional Foods Modulating Inflammation and Oxidative Stress. Elsevier, p. 605-626 22 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter
1 Scopus citations -
Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
Elbezanti, W. O., Al-Odat, O. S., Chitren, R., Singh, J. K., Srivastava, S. K., Gowda, K., Amin, S., Robertson, G. P., Nemmara, V. V., Jonnalagadda, S. C., Budak-Alpdogan, T. & Pandey, M. K., Sep 9 2022, In: Frontiers in Pharmacology. 13, 894535.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Hydrogel-Encapsulated Heterogenous Mesoporous Resin Catalyst for In Situ Anti-Cancer Agent Production under Biological Conditions
Nabavinia, M., Kanjilal, B., Pandey, M., Jonnalagadda, S., Hesketh, R., Martins-Green, M. & Noshadi, I., Dec 2022, In: Biomolecules. 12, 12, 1796.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations